2023 European Meeting of ISMPP

MAPPS-US-LB-010322 -60-


MAPPS-US-LB-010322 -76-

24–25 January

MAPPS-US-LB-010322 -78-

London, UK

Find us at booth 1

Share this page

2023 European Meeting of ISMPP, London, UK

Can we ever have true creativity without true inclusivity? How should the pharmaceutical industry respond to health equity issues? Do digital enhancements improve accessibility or do they just paper over the gap?

Effective innovation happens when we ask big questions. It’s part of what makes Oxford PharmaGenesis an award-winning, independent, global HealthScience communications consultancy. We innovate for clients through our transformative services. We offer expertise in publications, strategic medical communications, informatics and data science, patient engagement, value demonstration, Open Pharma, social media and more.

Join our healthy debate at the 2023 European Meeting of ISMPP and explore new frontiers with Oxford PharmaGenesis.

Meet us at our booth

Exploring new frontiers

Patient Engagement

Let’s explore increasing patient involvement

We are committed to making a tangible difference to patient health. Our team of dedicated patient engagement specialists can help you understand the impact of evolving healthcare innovations. Let’s reach out to make meaningful patient connections at every stage of the drug development continuum.

Open Pharma

Let’s explore the future of pharma

Open Pharma is driving positive change in the communication of pharma-sponsored research at the frontiers of open science. Our goal is to accelerate the transparency, accountability, accessibility and discoverability of medical research. Together with pharma, publishers, patients and other stakeholders, we are building trust in healthcare communications.

Medical Affairs

Let’s explore the evolving landscape of Medical Affairs

Medical affairs is being transformed by the drive towards patient-centered, digitally-enabled engagement. We partner with our clients by offering full support on all medical affairs activities throughout the product life cycle, from evidence generation and strategy planning to clear communication of medical content tailored to physicians, patients, regulators, payers and policy-makers.

Informatics and Data Science

Let’s explore where data could take you

The universe of available biomedical data is constantly expanding. To use all this data to improve decision-making demands an approach that sits at the intersection of healthcare information and technology: informatics. We help our clients navigate this dynamic and rapidly growing field. With our support, you’ll see through the data and discover powerful insights.

Value Demonstration

Let's explore ways to support patient access

Innovative and life-changing interventions need to be funded by healthcare systems worldwide and made available to the patients who need them the most. We help incorporate unmet need and health economic concepts into your strategies through effective communication and tactics to help support the reimbursement of new interventions and achieve broad patient access.

Strategic Medical Communications

Let’s explore new possibilities in medical communications

We apply a deep understanding of the science, audiences and channels to create persuasive medical communications across all forms of media. Our strategic planning process can take your medical communications to another level by connecting insights with medical objectives and evolving technological opportunities.


Lessons learned during ongoing development of the ACCORD reporting guideline for studies using consensus methodologies

Niall Harrison (Ogilvy Health UK), Amy Price (Stanford Anesthesia Summer Institute), Chris Winchester (Oxford PharmaGenesis), David Tovey (Journal of Clinical Epidemiology), Ellen L. Hughes (OPEN Health Communications), Esther J. van Zuuren (Leiden University Medical Centre), Keith Goldman (AbbVie), Mark Rolfe (Oxford PharmaGenesis), Patricia Logullo (Centre for Statistics in Medicine) and William T. Gattrell (Bristol Myers Squibb)

Development of an alternative to journal impact factor using a broader range of article-level metrics

Tomas Rees (Oxford PharmaGenesis), Shailesh Desai (Takeda), Gina D’Angelo (Takeda) and Eileen Hartman (Takeda)

Why did it go viral? An informatics-based case study of exaggerated language in news and social media

Hollie Rawlings (Oxford PharmaGenesis), Tomas Rees (Oxford PharmaGenesis), Lubaina Koti (Dasman Diabetes Institute), Avishek Pal (Novartis) and Andrew Liew (Oxford PharmaGenesis)

PubMed tags published articles with greater accuracy than Embase. Other biomedical databases provide insufficient data to enable comparative analysis

Joseph Cutteridge (York and Scarborough Teaching Hospitals NHS Foundation Trust) and Kim Wager (Oxford PharmaGenesis)

ORCID uptake in pharma-sponsored research

Caitlin Edgell (Oxford PharmaGenesis), Sarah Sabir (Oxford PharmaGenesis), Paul Farrow (Oxford PharmaGenesis), Shawna Sadler (ORCID), James Munday (Oxford PharmaGenesis), Christine Vanderlinden (GSK) and Santosh Mysore (GSK)

Assessing PubMed metatag usage for plain language summary discoverability

Adeline Rosenberg (Oxford PharmaGenesis), Slávka Baróniková (Galapagos), William T. Gattrell (Ipsen), Namit Ghildyal (Janssen), Tim J. Koder (Oxford PharmaGenesis), Taija Koskenkorva (Novartis), Andrew Liew (Oxford PharmaGenesis), Radha Narayan (Alexion), Joana Osório (Oxford PharmaGenesis), Valérie Philippon (UCB), Melissa Shane (Oxford PharmaGenesis), Catherine Skobe (Pfizer Inc.) and Kim Wager (Oxford PharmaGenesis)

Social media metrics of plain language summaries on Figshare

Adeline Rosenberg (Oxford PharmaGenesis), Caroline Halford (Springer Healthcare), Chirag Jay Patel (Cactus Communications), Michelle Adams (Pfizer Inc.), Andy Shepherd (Envision Pharma Group), Mike Gregg (Taylor & Francis Group), Joanne Walker (Becaris Publishing Limited) and Russell J. Craddock (Parexel International)

Evaluating the publication of randomized controlled trials in inflammatory bowel disease by trial outcome and journal attributes

Slavka Baronikova (Galapagos), Kim Wager (Oxford PharmaGenesis), Frances Thompson (Oxford PharmaGenesis), Iain Haslam (Aspire Scientific Ltd), Helen Woodroof (Aspire Scientific Ltd) and John Gonzaleza (Galapagos)

Accessibility of scientific information for non-English speakers: using browser-based tools to translate plain language summaries (PLS) and abstracts 

Claire Beeby (Oxford PharmaGenesis), Victoria Tomlinson (Oxford PharmaGenesis), Eleanor Raynsford (Ipsen) and Charles (Ipsen) 

Roundtable sessions

Much ado about access

13:20–14:55 GMT, Tuesday 24 January 2023 – Joana Osório and Paul Farrow

Innovating to improve sustainability in medical communications

13:20–14:55 GMT, Tuesday 24 January 2023 – Paul Tisdale

Creating consistent communication through effective scientific communication platform socialization

13:20–14:55 GMT, Tuesday 24 January 2023 – Gemma Rogers and Tomas Rees

Get in touch

If you want to speak to one of our team about how we can support you, please fill in the contact form below.